OBJECTIVES: Tenascin-C is a hexameric extracellular matrix glycoprotein that is expressed during embryonic development and re-expressed in proliferative processes such as wound healing and tumorigenesis. Stromal tenascin-C may block tumor invasion and thus have a significant influence on tumor spread and prognosis. METHODS: In the present study, tissue expression of stromal tenascin-C was studied by immunohistochemistry in a series of 314 patients with gastric cancer. RESULTS: Strong tenascin-C positivity was seen in the stroma of the tumor in 122 (39%) cases. There was a correlation between strong tenascin-C expression and low stage (p = 0.002), superficial tumor penetration (p = 0.02), location of tumor at the distal third of the stomach (p = 0.03), and potentially curative surgery (p = 0.008). No significant correlation was found between tenascin-C positivity and nodal status, distant metastases, age, Laurén classification, gender, tumor size, or Borrmann classification. The cumulative 5-year survival in patients with strong tenascin-C expression was 42% compared to 26% in those with negative-to-moderate expression (p = 0.0053). In multivariate survival analysis stratified for estimated cure of surgery, stage of disease was the only independent prognostic factor. CONCLUSION: In conclusion, tenascin-C expression seems to correlate with cancer related survival in patients with gastric cancer, but may not add significant prognostic information to that provided by TNM stage. Copyright 2003 S. Karger AG, Basel
OBJECTIVES:Tenascin-C is a hexameric extracellular matrix glycoprotein that is expressed during embryonic development and re-expressed in proliferative processes such as wound healing and tumorigenesis. Stromal tenascin-C may block tumor invasion and thus have a significant influence on tumor spread and prognosis. METHODS: In the present study, tissue expression of stromal tenascin-C was studied by immunohistochemistry in a series of 314 patients with gastric cancer. RESULTS: Strong tenascin-C positivity was seen in the stroma of the tumor in 122 (39%) cases. There was a correlation between strong tenascin-C expression and low stage (p = 0.002), superficial tumor penetration (p = 0.02), location of tumor at the distal third of the stomach (p = 0.03), and potentially curative surgery (p = 0.008). No significant correlation was found between tenascin-C positivity and nodal status, distant metastases, age, Laurén classification, gender, tumor size, or Borrmann classification. The cumulative 5-year survival in patients with strong tenascin-C expression was 42% compared to 26% in those with negative-to-moderate expression (p = 0.0053). In multivariate survival analysis stratified for estimated cure of surgery, stage of disease was the only independent prognostic factor. CONCLUSION: In conclusion, tenascin-C expression seems to correlate with cancer related survival in patients with gastric cancer, but may not add significant prognostic information to that provided by TNM stage. Copyright 2003 S. Karger AG, Basel
Authors: O Driemel; R Dahse; A Berndt; H Pistner; S G Hakim; L Zardi; T E Reichert; H Kosmehl Journal: Clin Oral Investig Date: 2006-11-17 Impact factor: 3.573
Authors: N Linder; C Haglund; M Lundin; S Nordling; A Ristimäki; A Kokkola; J Mrena; J-P Wiksten; J Lundin Journal: J Clin Pathol Date: 2006-09 Impact factor: 3.411
Authors: Han Saem Lee; Ji Yun Kim; Won Il Lee; Sung Jin Kim; Min Ji Ko; Sunjoo Jeong; Keerang Park; Han Choe; Heuiran Lee Journal: Oncol Lett Date: 2011-08-08 Impact factor: 2.967
Authors: Ann H Klopp; Lara Lacerda; Anshul Gupta; Bisrat G Debeb; Travis Solley; Li Li; Erika Spaeth; Wei Xu; Xiaomei Zhang; Michael T Lewis; James M Reuben; Savitri Krishnamurthy; Mauro Ferrari; Rogério Gaspar; Thomas A Buchholz; Massimo Cristofanilli; Frank Marini; Michael Andreeff; Wendy A Woodward Journal: PLoS One Date: 2010-08-16 Impact factor: 3.240